A randomized placebo-controlled safety and dose-finding study for the use of the IL-6 inhibitor clazakizumab in patients with life-threatening COVID-19 infection

Brief description of study

The purpose of this research study is to investigate the safety of treatment with an investigational drug called clazakizumab compared to a placebo (inactive substance) in critically ill patients who have been diagnosed with COVID-19 and have signs of respiratory failure. We think this drug might be effective based on the potential benefit of a similar drug in a small number of patients who developed similar life-threatening pulmonary failure after acquiring COVID-19. An investigational drug is one that has not been approved by the regulatory authorities such as the US Food and Drug Administration (FDA). Clazakizumab is an antibody drug (a protein made in yeast) that blocks another protein called interleukin 6 (IL-6) which is important in inflammation.




If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.